Prospective joint venture will accelerate precision medicine in Europe by harnessing innovations in high-throughput drug testing, 3D tumor cell culture, and AI analytics established at SEngine Precision Medicine to identify the best personalized therapeutic matches for patientsSEATTLE and PARIS, Oct. 05, 2021 (GLOBE NEWSWIRE) — SEngine Precision Medicine and the Institute Gustave Roussy, a leading comprehensive cancer center in Europe, today announced the execution of a term sheet toward the establishment of a joint venture based in Paris, France. The joint venture will aim to offer a next-generation diagnostic test, making it possible to predict a tumor’s response to different treatments. This joint effort will accelerate the development of personalized medicine in Europe based on technologies developed by SEngine in the evaluation of drugs as well as Gustave Roussy’s expertise in advancing 3D cell culture tumor models. The objective is to perform “organograms” to identify the best personalized therapeutic matches for patients. Since 2019, SEngine and Gustave Roussy have worked to demonstrate the feasibility of a cross-continental collaboration and will soon begin Phase I of a multi-site clinical trial, Organotreat, employing SEngine’s PARIS® Test to guide treatment selection for patients with metastatic colorectal cancer. Later phases of the trial will include over 300 advanced colorectal and pancreatic cancer patients, two pathologies with large unmet medical need. The joint venture will leverage data from the Organotreat clinical trial to drive clinical validation and commercialization of the PARIS® Test throughout Europe. “Joining SEngine’s expertise to our large-scale clinical trial on patient tumor avatars is a unique opportunity to assess next-generation personalized medicine based on cellular approaches,” said Fanny Jaulin, Ph.D., scientific coordinator for the Organotreat clinical trial and principal investigator of the Jaulin Lab within the Institute Gustave Roussy. “Current precision medicine approaches to cancer care are carried out using DNA sequencing of an individual’s cancer. This information comprises a unique mosaic of alterations, a language that is still in need of translation,” said Carla Grandori, MD, Ph.D., co-founder and Chief Executive Officer of SEngine Precision Medicine. “The PARIS® Test translates this genomic language through phenotypic drug testing culminating in an actionable report of ranked oncology drugs shown to improve patient outcomes.” “We are in a new era of Precision Oncology, and the Institute is the ideal partner to advance major innovations in the field,” noted Ulrich Mueller, Ph.D., Chief Business Officer of SEngine Precision Medicine. “Together with their network of physicians and scientists, we hope to save lives while reducing the cost of cancer care by ruling out potentially unnecessary treatments and matching the right drugs to the right patients.” About PARIS® TestThe PARIS® Test is a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with drug sensitivity testing of patient-derived live cells combined with robotics and AI-driven computational tools. SEngine’s CLIA certified PARIS® Test generates actionable drug sensitivity reports for patients and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer. Cancer derived cells grown in 3D outside the body maintain the functionality of the original tumor as well as its genomic characteristics. For cancers where a treatment path is not clear, such as many metastatic and recurrent cancers, the PARIS® Test provides crucial information to treating physicians to match the right drug to the right patient. About SEngine Precision MedicineSEngine Precision Medicine Inc. is a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D cultures utilizing patient specific tumor cells. As a spin-out from the world-renowned Fred Hutchinson Cancer Research Center, SEngine is leveraging over two decades of R&D in diagnostics and drug discovery. The Company is commercializing the PARIS® Test, a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with phenotypic testing of patient-derived live cells combined with robotics and AI-driven computational tools. SEngine’s CLIA certified PARIS® Test generates actionable drug sensitivity reports for patients with solid tumors. SEngine is also pursuing drug discovery via strategic collaborations with biopharmaceutical / pharma companies by deploying its precision oncology platform. Discover more at SengineMedicine.com and follow the latest news from SEngine on Twitter at @SEngineMedicine and on LinkedIn. Contact:reneevolpini@aol.com917-923-8117 About Gustave RoussyClassed as the leading European Cancer Centre and fifth in the world, Gustave Roussy is a hospital with comprehensive expertise and is devoted entirely to patients suffering from cancer. It is a source of diagnostic and therapeutic advances. Gustave Roussy caters to almost 50,000 patients per year and its approach is one that integrates research, patient care, and teaching. It is specialized in the treatment of all stages of cancer in patients of any age, including rare cancers and complex tumors. Care is personalized and combines the most advanced medical methods with an appreciation of the patient’s individual requirements. In addition to the quality of treatment offered, the physical, psychological and social aspects of the patient’s life are respected. 3,200 health professionals work on Gustave Roussy’s two campuses: Villejuif and Chevilly-Larue. Gustave Roussy brings together the essential skills required for the highest quality oncology research; a quarter of patients treated are included in clinical trials. For further information: www.gustaveroussy.fr/enFollow Gustave Roussy on social media on Twitter, Facebook, LinkedIn, InstagramPress contact: Claire Parisel, claire.parisel@gustaveroussy.fr, +33 1 42 11 50 59 , +33 6 17 66 00 26